SynthesisFrontiers in pharmacology2026
First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Zijing Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.